KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Net Cash Flow (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Net Cash Flow for 17 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 612.77% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $835.0 million through Dec 2025, up 2.33% year-over-year, with the annual reading at $835.0 million for FY2025, 2.33% up from the prior year.
  • Net Cash Flow hit $1.0 billion in Q4 2025 for Abbott Laboratories, up from $570.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $1.3 billion in Q2 2022 to a low of -$2.1 billion in Q1 2022.
  • Historically, Net Cash Flow has averaged $96.2 million across 5 years, with a median of $439.0 million in 2021.
  • Biggest five-year swings in Net Cash Flow: crashed 269.71% in 2022 and later soared 612.77% in 2025.
  • Year by year, Net Cash Flow stood at $510.0 million in 2021, then crashed by 53.53% to $237.0 million in 2022, then tumbled by 31.65% to $162.0 million in 2023, then decreased by 12.96% to $141.0 million in 2024, then skyrocketed by 612.77% to $1.0 billion in 2025.
  • Business Quant data shows Net Cash Flow for ABT at $1.0 billion in Q4 2025, $570.0 million in Q3 2025, and $368.0 million in Q2 2025.